Journal profile · Medicine-Infectious Diseases
Infectious Diseases Now
ISSN 2666-9927 · eISSN 2666-9919 · Elsevier
Infectious Diseases Now: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.98; hybrid open access; APC about USD 1,640; median 79 days to acceptance (100 articles, last 24 months); 146 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Infectious Diseases Now is published by Elsevier and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Antibiotic Use and Resistance, COVID-19 Clinical Research Studies and Antibiotic Resistance in Bacteria, together about 21.7% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
The journal Infectious Diseases Now (formerly Médecine et Maladies Infectieuses) publishes in English the highest quality original material, both scientific and clinical, on the various infectious pathologies and their pathogens. The journal's areas of study include clinical, prevention, biology, nosocomial infections, epidemiology and therapeutics. Issues contain editorials, original articles, general reviews, short communications and letters to the editor.Infectious Diseases Now is the official journal of the SPILF, French Infectious Diseases Society (Société de Pathologie Infectieuse de Langue Française).Infectious Diseases Now follows the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, issued by the International Committee of Medical Journal Editors (ICMJE Recommendations), and follows COPE's guidelines edited by the Committee on Publication Ethics.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Infectious Diseases
Editor-in-chief Jean-Paul StahlPublisher website
Editorial board by country: none in mainland China; most named France 22, Italy 3, United States 2, Germany 1 (28 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Antibiotic Use and ResistanceImmunology and Microbiology8.9%
- COVID-19 Clinical Research StudiesMedicine7.3%
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology5.6%
- SARS-CoV-2 and COVID-19 ResearchMedicine5.2%
- Orthopedic Infections and TreatmentsMedicine5.2%
- Antibiotics Pharmacokinetics and EfficacyMedicine4.8%
- Pneumonia and Respiratory InfectionsMedicine4.7%
- Vaccine Coverage and HesitancySocial Sciences4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.98LetPub ·
- Impact factor (publisher)
- 3Publisher website ·
- CiteScore 2026-06
- 3.8LetPub ·
- CiteScore (publisher)
- 3.8Publisher website ·
- SJR 2026-06
- 0.78LetPub ·
- SNIP 2026-06
- 0.93LetPub ·
- h-index
- 29OpenAlex ·
- i10-index
- 113OpenAlex ·
- 2-year mean citedness
- 2.33OpenAlex ·
- Self-citation rate
- 3.3%LetPub ·
- Share of gold OA articles
- 47.44%LetPub ·
Volume
- Articles per year
- 106LetPub ·
Articles by year OpenAlex count · 1,000 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 67 | 36 | 10 |
| 2025 | 146 | 89 | 255 |
| 2024 | 105 | 64 | 477 |
| 2023 | 126 | 79 | 870 |
| 2022 | 103 | 68 | 877 |
| 2021 | 399 | 154 | 2,048 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
79 daysMedian, submission to acceptance · P25–P75 40 days – 133 days
- Acceptance to online
- median 2 days (100 articles)
- Submission to online
- median 83 days
- Sample
- 100 articles with submission and acceptance dates (220 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 8 daysPublisher website ·
- First decision after review
- 54 daysPublisher website ·
- Submission to acceptance
- 87 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 1,640 / EUR 1,500 / GBP 1,320 / JPY 203,410 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- ≥ 1
- Reference style
- Vancouver
- Highlights
- Required
Article types accepted5, with length limits
- letter to the editorEnables the author to comment on an article that has already been published and to present a relevant personal experience. Clinical case can't be presented in t…main text ≤ 1,000 words · references ≤ 10
- mini reviewCan be either invited by the Editorial Committee or submitted spontaneously by authors. Provides an update on a particular aspect of a condition (treatment, dia…main text ≤ 3,000 words · abstract ≤ 250 words · figures and tables ≤ 5 · references ≤ 35
- original articleProvides information from a clinical, biological, or epidemiological study. The results should be novel and have never published in a peer-reviewed or reference…main text ≤ 3,500 words · abstract ≤ 250 words · figures and tables ≤ 5 · references ≤ 40
- protocolProtocol reports is the opportunity for authors to publish technical features of their study, before results and final publication, so they can spare space in t…main text ≤ 3,000 words · abstract ≤ 200 words · references ≤ 30
- short communicationThis is a way to report original results or case in a condensed form. Title in American English10 authors maximum1,500 words maximumEnglish abstract, 150 wordsH…main text ≤ 1,500 words · abstract ≤ 150 words · figures and tables ≤ 3 · references ≤ 20
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
This journal follows a double anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- ISSN
- 2666-9927
- Electronic ISSN
- 2666-9919
- Society / sponsor
- SPILF
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Infectious Diseases Now
What CAS zone is Infectious Diseases Now in?
In the 2025 upgraded edition of the CAS Journal Ranking, Infectious Diseases Now is in Zone 4 of Medicine, and in Zone 4 of the minor category Infectious Diseases. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Infectious Diseases Now?
The latest impact factor listed by LetPub is 2.98; CiteScore 3.8, h-index 29.
How long does peer review take at Infectious Diseases Now?
Based on the dates recorded on 100 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 79 days (interquartile range 40–133 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Infectious Diseases Now?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: ≥ 1; Reference style: Vancouver; Highlights: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Infectious Diseases Now based?
Of the 28 board members whose country the journal's board page names, none are in mainland China; the countries named most often are France (22), Italy (3) and United States (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Infectious Diseases Now?
According to LetPub and DOAJ records, Infectious Diseases Now is indexed in SCIE and Scopus.
Is Infectious Diseases Now open access, and what is the APC?
Infectious Diseases Now is a hybrid journal. For open-access publication: APC about USD 1,640.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-30). Last updated: .